Toward a functional definition of a "rare disease" for regulatory authorities and funding agencies

Value in Health

Volumn 17, Issue 8, 2014, Pages 757-761

  Clarke, Joe T R ^a   Coyle, Doug ^b   Evans, Gerald ^c   Martin, Janet ^d,e   Winquist, Eric ^d,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d WESTERN UNIVERSITY   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

drug development; drug reimbursement; orphan drugs; rare disease

Indexed keywords

AUTHORITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG INDUSTRY; FEASIBILITY STUDY; FUNDING; HUMAN; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL; RARE DISEASE; REIMBURSEMENT; REVIEW; SCIENTIST; CLASSIFICATION; DRUG APPROVAL; DRUG CONTROL; FINANCIAL MANAGEMENT; ORGANIZATION AND MANAGEMENT; RARE DISEASES;

DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG INDUSTRY; FINANCING, ORGANIZED; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; RARE DISEASES;

EID: 84916244895     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.08.2672     Document Type: Article

References (31)

1. M.E. Haffner Orphan products: origins, progress, and prospects Annu Rev Pharmacol Toxicol 31 1991 603 620
2. M.E. Haffner Orphan drug product regulation - United States. Int J Clin Pharmacol Ther 40 2002 84 88
3. Orphan Drug Act, Pub L. No. 97-414, Sect. J(b), 21 USC Sect. 360aa, note 551 (1983).
4. M.E. Haffner Adopting orphan drugs - two dozen years of treating rare diseases N Engl J Med 354 2006 445 447
5. A. Denis, L. Mergaert, and C. Fostier Issues surrounding orphan diseases and orphan drug policies in Europe Appl Health Econ Health Policy 8 2010 343 350
6. A. Fehr, P. Thürmann, and O. Razum Drug development for neglected diseases: a public health challenge Tropical Med Int Health 11 2006 1335 1338
7. A. Laupacis, D. Feeny, A.S. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 1992 473 481
8. M.F. Drummond, D.A. Wilson, and P. Kanavos Assessing the economic challenges posed by orphan drugs Int J Technol Assess Health Care 23 2007 36 42
9. R.Y. Cheung, J.G. Cohen, and P. Illingworth Orphan drug policies: implications for the United States, Canada and developing countries Health Law J 12 2004 83 200
10. E. Hernberg-Ståhl, and M. Reljanović Orphan Drugs 2013 Woodhead Publishing Cambridge
11. B.D. Lehmann, and J.A. Pietenpol Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes J Pathol 232 2014 142 150
12. L.A. Clark, D. Watson, and S. Reynolds Diagnosis and classification of psychopathology: challenges to the current system and future directions Ann Rev Psychol 46 1995 121 153
13. I.D. Young, P.S. Harper, R.G. Newcombe, and I.M. Archer A clinical and genetic study of Hunter's syndrome, 2: differences between the mild and severe forms J Med Genet 19 1982 408 411
14. I.D. Young, and P.S. Harper Mild form of Hunter's syndrome: clinical delineation based on 31 cases Arch Dis Child 57 1982 828 836
15. K.J. Valenzano, K. Richie, and A.C. Powe Jr Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders Assay Drug Dev Technol 9 2011 213 235
16. E. Winquist, C.M. Bell, and J.T. Clarke An evaluation framework for funding drugs for rare diseases Value Health 15 2012 982 986
17. E. Winquist, D. Coyle, and J.T. Clarke Application of a policy framework for the public funding of drugs for rare diseases J Gen Int Med 29 Suppl. 3 2014 774 779
18. R. Schiffmann, M. Ries, and D. Blankenship Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa Genet Med 15 2013 983 989
19. P.S. Kishnani, W.-L. Hwu, and H. Mandel A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease J Pediatr 148 2006 671 676
20. R.J. Desnick, Y.A. Ioannon, and C.M. Eng α-Galactosidase A deficiency: Fabry disease C.R. Scriver, A.L. Beaudet, W.S. Sly, The Molecular and Metabolic Bases of Inherited Disease 8th ed. 2001 McGraw-Hill New York
21. P.J. Meikle, J.J. Hopwood, A.E. Clague, and W.F. Carey Prevalence of lysosomal storage disorders JAMA 281 1999 249 254
22. M. Spada, S. Pagliardini, and M. Yasuda High incidence of later-onset Fabry disease revealed by newborn screening Am J Hum Genet 79 2006 31 40
23. W.-L. Hwu, YY-H Chien, and N.-C. Lee Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A) Hum Mutat 30 2009 1397 1405
24. K.E. Muller, L.M. Lavange, S.L. Ramey, and C.T. Ramey Power calculations for general linear multivariate models including repeated measures applications J Am Stat Assoc 87 1992 1209 1226
25. Y. Guo, H.L. Logan, D.H. Glueck, and K.E. Muller Selecting a sample size for studies with repeated measures BMC Med Res Method 13 2013 100
26. J.T.R. Clarke, D. Amato, and R. Deber Managing public payment for high-cost/high-benefit treatment: enzyme replacement therapy of Gaucher disease in Ontario CMAJ 165 2001 595 596
27. S. Sirrs, J.T. Clarke, and D.G. Bichet Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative Mol Genet Metab 99 2010 367 373
28. S. Sirrs, D.G. Bichet, and R. Casey Outcomes of patients treated through the Canadian Fabry Disease Initiative Mol Genet Metab 111 2014 499 506
29. M. Connock, A. Burls, and E. Frew The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review Health Technol Assess 10 2006 iii iv ix-136
30. Institute of Medicine. Strengthening a workforce for innovative regulatory science in therapeutics development. Workshop summary, 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK92889/?report=reader. [Accessed July 2, 2014].
31. European Medicines Agency The European Medicines Agency Road Map to 2015: The Agency's Contribution to Science, Medicines, Health, Draft for Public Consultation 2010 European Medicines Agency London